HER2 inhibitor monoclonal antibody

This page covers all HER2 inhibitor monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HER2 (human epidermal growth factor receptor 2), HER2 (Human Epidermal Growth Factor Receptor 2).

Targets

HER2 (human epidermal growth factor receptor 2) · HER2 (Human Epidermal Growth Factor Receptor 2)

Marketed (1)

• pertuzumab (P) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Oncology
  Pertuzumab is a monoclonal antibody that blocks HER2 dimerization, preventing HER2 from pairing with other HER receptors and inhibiting tumor cell growth signaling.

Phase 3 pipeline (5)

• Pertuzumab IV · Hoffmann-La Roche · Oncology
  Pertuzumab is a monoclonal antibody that blocks HER2 dimerization, preventing HER2 from pairing with other HER receptors and inhibiting tumor cell growth signaling.
• EU-Perjeta® · Shanghai Henlius Biotech · Oncology
  EU-Perjeta is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER family receptors, inhibiting tumor cell growth signaling.
• Pertuzumab (Perjeta®) · Zydus Lifesciences Limited · Oncology
  Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.
• SHR-A1811 Injection ； Pertuzumab Injection · Jiangsu HengRui Medicine Co., Ltd. · Oncology
  Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, inhibiting tumor cell growth signaling.
• Pertuzumab Injection · RemeGen Co., Ltd. · Oncology
  Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.